Invesco
MCRB icon

Invesco’s Seres Therapeutics MCRB Stock Holding History

Invesco’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102K Sell
12,974
-1,573
-11% -$12K ﹤0.01% 3731
2026
Q1 		$129K Buy
14,547
+187
+1% +$2.19K ﹤0.01% 3592
2025
Q4 		$214K Buy
14,360
+3,918
+38% +$68.3K ﹤0.01% 3502
2025
Q3 		$201K Buy
+10,442
New +$167K ﹤0.01% 3564
2025
Q2 		– Sell
-6,829
Closed -$95.6K – 3824
2025
Q1 		$95.6K Buy
6,829
+4,500
+193% +$70.5K ﹤0.01% 3629
2024
Q4 		$38.7K Sell
2,329
-432
-16% -$7.02K ﹤0.01% 3714
2024
Q3 		$52.2K Buy
2,761
+798
+41% +$16.2K ﹤0.01% 3684
2024
Q2 		$28.4K Sell
1,963
-1,185
-38% -$19.8K ﹤0.01% 3861
2024
Q1 		$48.7K Buy
3,148
+298
+10% +$6.43K ﹤0.01% 3804
2023
Q4 		$79.8K Buy
2,850
+682
+31% +$17.9K ﹤0.01% 3712
2023
Q3 		$103K Buy
2,168
+113
+5% +$8.62K ﹤0.01% 3713
2023
Q2 		$197K Buy
2,055
+304
+17% +$33.1K ﹤0.01% 3616
2023
Q1 		$199K Buy
1,751
+41
+2% +$4.43K ﹤0.01% 3618
2022
Q4 		$191K Sell
1,710
-26,770
-94% -$3.59M ﹤0.01% 3696
2022
Q3 		$3.66M Buy
28,480
+26,943
+1,753% +$2.76M ﹤0.01% 2376
2022
Q2 		$106K Sell
1,537
-49
-3% -$4.22K ﹤0.01% 3875
2022
Q1 		$225K Hold
1,586
– – ﹤0.01% 3751
2021
Q4 		$264K Sell
1,586
-426
-21% -$67.7K ﹤0.01% 3666
2021
Q3 		$281K Buy
2,012
+330
+20% +$64.6K ﹤0.01% 3673
2021
Q2 		$802K Buy
1,682
+954
+131% +$403K ﹤0.01% 3220
2021
Q1 		$300K Buy
728
+209
+40% +$96.2K ﹤0.01% 3550
2020
Q4 		$254K Sell
519
-3,178
-86% -$1.86M ﹤0.01% 3473
2020
Q3 		$2.09M Buy
+3,697
New +$1.23M ﹤0.01% 2476

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Invesco's MCRB Position: Q2 2026 in Review

Invesco reduced its Seres Therapeutics (MCRB) stake by 11% in Q2 2026, selling an estimated $12K and leaving 12,974 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #3731.

Invesco first reported a position in MCRB in Q3 2020 and has held it in 23 quarters since. The position peaked at $3.66M in Q3 2022. 35 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

  • Invesco held 12,974 shares of Seres Therapeutics worth $102K as of Q2 2026.
  • Invesco sold 1,573 Seres Therapeutics shares in Q2 2026, an estimated $12K.
  • Seres Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3731 holding.
  • Invesco first reported a position in Seres Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Invesco's Seres Therapeutics position peaked at $3.66M in Q3 2022.
  • 35 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.